NASHUA, N.H., Jan. 9 /PRNewswire-FirstCall/ -- iCAD, Inc. , an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, today announced that Steven Rappaport, a partner with RZ Capital, LLC, and Dr. Lawrence Howard, general partner of Hudson Ventures, L.P. have been appointed to the Company's Board of Directors. Mr. Rappaport and Dr. Howard bring many years of legal and management experience from work with financial services, technology and investment firms to iCAD.
"iCAD is pleased to welcome Steve and Larry to our Board of Directors," said Ken Ferry, Chief Executive Officer of iCAD, Inc. "Their extensive experience working with high growth technology companies will complement and enhance our current Board and we look forward to leveraging their past successes and experience to advance our Company and our line of early cancer detection products."
Since July 2002, Mr. Rappaport has been a partner of RZ Capital, LLC, a private investment firm. From March 1995 to July 2002, Mr. Rappaport was Director, President and Principal of Loanet, Inc., an online real-time accounting service which was acquired by SunGard Data Systems in May 2001. Prior to Loanet, Mr. Rappaport served as Director and then Executive Vice President of Metallurg, Inc. and President of Metallurg's subsidiary, Shieldalloy Corporation. From March 1987 to March 1992, Mr. Rappaport was Director, Executive Vice President and Secretary of Telerate, Inc., an electronic distributor of financial information, which was ultimately acquired by Dow Jones. Prior to Telerate, Mr. Rappaport practiced corporate and tax law at the New York Law firm of Harman & Craven. He became a partner in the firm in 1979.
Mr. Rappaport currently serves as an Independent Director and Audit Committee member of Presstek, Inc. Mr. Rappaport also serves as Chairman, Director and/or Audit Committee member of a number of open and closed end American Stock Exchange funds of which Credit Suisse is the investment adviser. He also serves as a Director on the boards of several privately-held companies.
Since March 1997, Dr. Howard has been a general partner of Hudson Ventures, L.P. (formally known as Hudson Partners, L.P.) as well as a managing member of Hudson Management Associates LLC, a limited liability company that provides management services. Since November of 2000, Dr. Howard has been a general partner of Hudson Venture Partners II, and a limited partner of Hudson Venture II, L.P. He was a Founder, and has been a Director of Presstek, Inc., where he served various officer positions from October 1987 to June 1993, most recently as Chief Executive Officer.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer- Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by over one thousand women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit www.icadmed.com.
For iCAD, contact Darlene Deptula-Hicks, Executive VP and CFO at 603-882-5200 or via email at ddeptula@icadmed.com For iCAD Investor Relations, contact Kevin McGrath of Cameron Associates at 212-245-4577 or via email at kevin@cameronassoc.com For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at 781-684-0770 or via e-mail at icad@schwartz-pr.com
iCAD, Inc.CONTACT: Darlene Deptula-Hicks, Executive VP and CFO of iCAD, Inc.,+1-603-882-5200, or ddeptula@icadmed.com; or Investor Relations, KevinMcGrath of Cameron Associates, +1-212-245-4577, or kevin@cameronassoc.com;or Public Relations, Wendy Ryan of Schwartz Communications,+1-781-684-0770, or icad@schwartz-pr.com, both for iCAD, Inc.
Web site: http://www.icadmed.com/
